Patents Assigned to Centre for Addiction and Mental Health
-
Patent number: 11763929Abstract: A medical tool is described for supporting an individual suffering from a mental condition or disorder characterized by auditory psychosis symptoms. The tool can assist in training the individual to distinguish between an acute auditory psychosis episode and ambient sounds. The tool can monitor for a non-audio input by a patient, where the input represents an indication that the patient is hearing sounds potentially symptomatic of psychosis. A microphone can monitor ambient sounds, which are tested against a threshold to determine and whether an auditory psychosis episode may be occurring.Type: GrantFiled: August 12, 2022Date of Patent: September 19, 2023Assignee: Centre For Addiction And Mental Health & Memotext CorporationInventors: Sean Andrew Kidd, Amos Adler, Hesamaldin Nekouei, Linda Kaleis
-
Patent number: 11753412Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.Type: GrantFiled: December 15, 2020Date of Patent: September 12, 2023Assignees: UWM Research Foundation, Inc., Centre for Addiction and Mental Health, University of Belgrade—Faculty of PharmacyInventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
-
Patent number: 11684647Abstract: A method of treating or preventing postpartum blues or depression is described, comprising administering to a subject in need thereof: an antioxidant source; a tryptophan composition comprising from 1.0 g to 5.0 g of tryptophan; and a tyrosine composition comprising from 2.0 g to 50 g of tyrosine. The antioxidant source may comprise a food or an extract derived from such a food as grapes, berries such as blueberries, citrus fruit, pomegranate, tomato, squash, carrot, sweet potato, dark green vegetables, beets, leafy vegetables, Brassica oleracea vegetables, peppers, melons, pineapples, lentils, plant oils, and/or tree nuts.Type: GrantFiled: November 6, 2020Date of Patent: June 27, 2023Assignee: CENTRE FOR ADDICTION AND MENTAL HEALTHInventor: Jeffrey H. Meyer
-
Patent number: 11104952Abstract: The invention provides genetic markers of severe suicidal behavior, related compositions, computer systems, and methods.Type: GrantFiled: November 19, 2015Date of Patent: August 31, 2021Assignee: Centre for Addiction and Mental HealthInventors: Clement C. Zai, James L. Kennedy
-
Patent number: 10906909Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.Type: GrantFiled: March 20, 2017Date of Patent: February 2, 2021Assignees: UWM Research Foundation, Inc., Centre for Addiction and Mental Health, University of Belgrade—Faculty of PharmacyInventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
-
Patent number: 10828343Abstract: Kits for the treatment or prophylaxis of depressed mood are described, for subjects with increased MAO-A levels, excessive crying, or subjects within or beyond the 5-day postpartum period. The kits are used to implement a method by which the subject is administered an antioxidant source on at least the first day of a 3 to 5 day regime; a tryptophan composition on the evening of the penultimate treatment day, simultaneously or following the antioxidant source; and a tyrosine composition the day after the tryptophan composition, on the final treatment day. The kit comprises an antioxidant source which may comprise or be derived from blueberries. Individuals with depressed mood due to perimenopause, alcohol use disorders or withdrawal, or who are up to or beyond 18-months postpartum, may benefit from the kits. The kits described may reduce the likelihood of advancing from depressed mood to depression.Type: GrantFiled: October 17, 2019Date of Patent: November 10, 2020Assignee: CENTRE FOR ADDICTION AND MENTAL HEALTHInventor: Jeffrey H. Meyer
-
Publication number: 20200270693Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Applicants: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20200270695Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Applicants: The Hospital For Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Patent number: 10745736Abstract: Disclosed is a method for diagnosing a mood disorder or susceptibility to a mood disorder, including depressive disorders and bipolar disorder, from a biological sample taken from a subject. The method includes detecting markers of monoamine oxidase-A (MAO-A) in the biological sample; determining MAO-A concentration from the markers; and correlating the MAO-A concentration in the biological sample to a control group which does not have a mood disorder in order to diagnose or determine susceptibility to the mood disorder in the subject. Also disclosed is a method of detecting peripheral markers of MAO-A for the diagnosis of a mood disorder or susceptibility to a mood disorder. Also provided are polypeptide markers.Type: GrantFiled: October 1, 2015Date of Patent: August 18, 2020Assignee: CENTRE FOR ADDICTION AND MENTAL HEALTHInventors: Jeffrey Meyer, Ken Evans, Jian Chen, Suzanne Ackloo, Moyez Dharsee
-
Patent number: 10662475Abstract: The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or disorder based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (AIWG). The methods of the invention also provide for different treatments, or different treatment regimens, for the subject depending on the subject's risk of AIWG. Related compositions, in the form of kits, systems, and computer-readable media are also provided.Type: GrantFiled: February 27, 2015Date of Patent: May 26, 2020Assignee: Centre for Addiction and Mental HealthInventors: Arun K. Tiwari, Eva J. Brandl, Nabilah I. Chowdhury, Vanessa F. Gonçalves, Jennie G. Pouget, James L. Kennedy, Daniel J. Mueller, Clement C. Zai
-
Patent number: 10577658Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: GrantFiled: March 7, 2018Date of Patent: March 3, 2020Assignees: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Patent number: 10577657Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: GrantFiled: March 7, 2018Date of Patent: March 3, 2020Assignees: The Hospital For Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Patent number: 10526653Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.Type: GrantFiled: February 24, 2015Date of Patent: January 7, 2020Assignees: The Centre for Addiction and Mental Health, The Hospital for Sick ChildrenInventors: Stephen W Scherer, John B Vincent
-
Patent number: 10478467Abstract: A method for the treatment or prophylaxis of depressed mood is described, for subjects with increased MAO-A levels, subjects prone to excessive crying, or beyond 5-days postpartum. The subject is administered an antioxidant source on at least the first day of a 3 to 5 day regime; a tryptophan composition on the evening of the penultimate treatment day, simultaneously or following the antioxidant source; and a tyrosine composition the day after the tryptophan composition, on the final treatment day. The antioxidant source may comprise blueberries or another anthocyanin-containing fruit, vegetable, nut, legume, or a juice or extract thereof. Individuals with depressed mood due to perimenopause, due to an alcohol use disorder or withdrawal therefrom, or who are in a postpartum period up to or beyond 18-months, may benefit from the treatment regime. The described method can reduce the likelihood of advancing from depressed mood to postpartum depression in the postpartum period.Type: GrantFiled: June 26, 2018Date of Patent: November 19, 2019Assignee: Centre for Addiction and Mental HealthInventor: Jeffrey H. Meyer
-
Patent number: 10435748Abstract: Provided are polymorphic markers defined by SEQ ID Nos:1-5 which are associated with suicide risk. Also provided are methods of use of such markers as well as kits for identifying the presence of markers.Type: GrantFiled: December 23, 2014Date of Patent: October 8, 2019Assignee: Centre for Addiction and Mental HealthInventors: Clement C. Zai, James L. Kennedy
-
Patent number: 10302625Abstract: Provided are methods for determining the level of microglial activation in the brain of a subject by measuring blood Prostaglandin E2 (PGE2), Prostaglandin F2?, or both, and C-Reactive Protein (CRP) concentrations in a sample obtained from a subject, wherein the ratio of [PGE2]/[CRP], [PGF2?]/[CRP], or both, is indicative of the level of microglial activation in the brain of the subject.Type: GrantFiled: January 15, 2016Date of Patent: May 28, 2019Assignee: Centre for Addiction and Mental HealthInventor: Jeff Meyer
-
Patent number: 10301678Abstract: Provided is a method of predicting a subject's weight response to antipsychotic drug treatment by obtaining a biological sample comprising genomic DNA from the subject and determining the presence or absence of one or more polymorphisms in the GABRA2 gene of the subject, wherein the presence of said one or more polymorphisms is predictive of the subject's weight change in response to antipsychotic drug treatment. The method also may comprise additional steps including treating the subject. Kits and components thereof are also provided.Type: GrantFiled: October 17, 2014Date of Patent: May 28, 2019Assignee: Centre for Addiction and Mental HealthInventors: Clement C. Zai, James L. Kennedy, Daniel J. Mueller
-
Publication number: 20180265926Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 7, 2018Publication date: September 20, 2018Applicants: The Hospital For Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Publication number: 20180265927Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.Type: ApplicationFiled: March 7, 2018Publication date: September 20, 2018Applicants: The Hospital for Sick Children, Centre for Addiction and Mental HealthInventors: Berge A. Minassian, John B. Vincent
-
Patent number: 10034852Abstract: A method of treating or preventing depressed mood is described, such as for treating or preventing postpartum blues or depression or other conditions associated with increased MAO-A levels. The method comprises administering to a subject an antioxidant source at least once between day-1 to day-5 postpartum (or on treatment days 1 to 5 of a non-postpartum regimen); an optional tryptophan composition on the evening of day-3 to day-5, simultaneously or following the antioxidant source; and a tyrosine composition the day after administering the tryptophan composition, for example on day-5.Type: GrantFiled: June 12, 2015Date of Patent: July 31, 2018Assignee: CENTRE FOR ADDICTION AND MENTAL HEALTHInventor: Jeffrey H. Meyer